Celcuity, Inc. (NASDAQ:CELC) Receives Average Recommendation of “Moderate Buy” from Analysts

Celcuity, Inc. (NASDAQ:CELC) has been given an average recommendation of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating and eleven have issued a buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $150.2727.

CELC has been the subject of a number of analyst reports. Citizens Jmp raised their price target on shares of Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a research note on Monday, May 4th. Weiss Ratings lowered Celcuity from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 price target on shares of Celcuity in a research note on Thursday, March 12th. Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a research note on Thursday. Finally, Wall Street Zen lowered shares of Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th.

Celcuity Trading Up 1.5%

Shares of CELC stock opened at $132.88 on Friday. Celcuity has a 52-week low of $10.50 and a 52-week high of $151.02. The stock has a market cap of $6.48 billion, a price-to-earnings ratio of -34.07 and a beta of 0.09. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The firm has a fifty day moving average of $123.09 and a 200-day moving average of $110.94.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.10. On average, equities research analysts forecast that Celcuity will post -3.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Celcuity

In other Celcuity news, Director Richard E. Buller sold 9,000 shares of Celcuity stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of Celcuity stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total value of $3,517,000.00. Following the completion of the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. The trade was a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 37,000 shares of company stock valued at $5,111,950. Corporate insiders own 13.33% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Avoro Capital Advisors LLC bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $310,302,000. NEA Management Company LLC grew its stake in shares of Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. State Street Corp grew its stake in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock valued at $163,343,000 after purchasing an additional 914,887 shares during the last quarter. Apis Capital Advisors LLC bought a new stake in shares of Celcuity during the third quarter valued at approximately $38,334,000. Finally, UBS Group AG grew its stake in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock valued at $42,211,000 after purchasing an additional 769,891 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.